1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Gland Pharma Limited

Gland Pharma Limited

GLAND.BO
Gland Pharma LimitedIN flagBombay Stock Exchange
2,231.95
INR
-43.30
- -
367.73BMarket Cap
Gland Pharma Limited
GLAND.BO
(Bombay Stock Exchange)

Recent

price

2,231.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
96.77
122.07
157.5
216.58
267.08
218.17
342.54
340.92
- -
347.21
Revenue per Share
19.66
27.67
47.33
63.07
73.81
47.44
46.9
42.4
- -
46.75
Basic EPS, GAAP
7.16
3.03
31.01
23.8
16.37
8.56
36.34
31.6
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
20
- -
- -
Dividend per Share
111.24
138.91
186.25
255.51
319.87
366.37
413.13
435.42
- -
- -
Book Value per Share
147.62
175.28
223.31
373.44
435.27
482.7
508.15
533.96
- -
- -
Tangible Book Value per Share
163
163
163
158
164
165
165
165
- -
165
Basic Weighted Avg Shares
15,801
19,931
25,718
34,236
43,841
35,919
56,417
56,165
64,306
57,204
Sales/Revenue/Turnover
29
30.8
33.54
35.16
31.94
24.22
17.66
15.86
18.75
17.22
Operating Margin (%)
784
821
946
988
1,103
1,467
3,446
3,779
4,237
3,870
Depreciation Expense
3,211
4,519
7,729
9,970
12,117
7,810
7,725
6,985
10,273
7,702
Net Income, GAAP
35.98
34.16
22.16
25.31
25.14
25.94
31.79
34.27
29.86
33.44
Effective Tax Rate (%)
20.32
22.67
30.05
29.12
27.64
21.74
13.69
12.44
15.98
13.46
Profit Margin (%)
13,530
18,247
24,873
46,111
52,701
61,717
42,468
52,181
59,184
- -
Working Capital
66
60
50
47
45
37
1,412
1,072
932
- -
LT Debt
24,104
28,620
36,462
59,032
71,576
79,587
87,238
91,507
103,580
- -
Total Equity
- -
15.23
20.54
18.74
15.99
8.55
7.98
6.28
8.37
- -
Return on Invested Capital (%)
- -
22.13
29.23
28.18
26.11
13.92
11.92
9.9
26.98
203.5
Return on Capital (%)
- -
22.12
29.11
28.16
26.09
13.85
12.04
9.99
28.58
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
2,066
- -
LT Borrowings
- -
777
- -
LT Finance Leases
- -
295
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
165
- -
Market Capitalization
293,214
262,298
301,825

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
67,829
- -
Cash, Cash Equivalents & STI
- -
29,522
- -
Accounts Receivable, Net
- -
15,165
- -
Inventories
- -
16,852
- -
Total Current Liabilities
- -
15,648
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
2,066
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.03%
13.19%
Free Cash Flow
- -
47.78%
3.15%
Net Income, GAAP
- -
4.48%
47.07%
Sales/Revenue/Turnover
- -
16.22%
14.5%
Total Cash Common Dividend
- -
- -
-10%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,087
13,734
15,452
15,145
56,417
2025
14,017
14,058
13,841
14,249
56,165
2026
15,056
16,954
17,428
- -
64,306

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.79
11.78
11.65
- -
46.9
2025
8.73
9.93
12.42
11.32
42.4
2026
13.08
15.87
22.26
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
20
2026
- -
- -
- -
- -
- -
Similar Companies
Grifols, S.A. (GRFS)
SMS Pharmaceuticals Limited (SMSPHARMA.BO)
Johnson & Johnson (JNJ.DE)
Daiichi Sankyo Company, Limited (DSKYF)
Zhejiang Int'l Group Co.,Ltd. (000411.SZ)
Abbott India Limited (ABBOTINDIA.NS)
Business
Gland Pharma Limited, founded in 1978 and headquartered in Hyderabad, India, manufactures and markets generic injectable pharmaceuticals with a focus on complex sterile injectables for oncology, ophthalmics, and other therapeutic areas including anti-diabetics, anti-infectives, anti-neoplastics, and blood-related treatments; its core offerings encompass liquid vials, lyophilized vials, pre-filled syringes, ampoules, infusion bags, and drops, with ongoing development in peptides, long-acting injectables, suspensions, hormonal products, pens, and cartridges. The company operates seven manufacturing facilities in India, provides contract development and manufacturing organization (CDMO) services, and supplies products to over 60 countries across the United States, Europe, Canada, Australia, India, and other markets through a primarily business-to-business model, supported by majority promoter Shanghai Fosun Pharma. Recent developments include the 2023 acquisition of Cenexi to bolster European CDMO capabilities, leadership changes with Srinivas Sadu as Executive Chairman and Shyamakant Giri as CEO effective January 2025, a 250% expansion of GLP-1 cartridge production capacity from 40 million to 140 million units announced in 2025 alongside the launch of partnered GLP-1 product Liraglutide, multiple US product approvals and launches such as Eribulin in 2024 with six complex injectables launched and three pending as of early 2025 addressing a $6.5 billion market opportunity, and 20 Ready-to-Use infusion bag filings with 14 approvals targeting $659 million in US sales.